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INTRODUTION 
  
             The WHO [world health organization] document that the vast majority 
of people (75 – 80%) living  in the developing world and industrialized nation 
prefer to traditional remedies for common ailments and  chronic disease. Due to 
the light cost of modern Hospitalization and expensive drugs and toxic with 
iatrogenic factors. 
 
 Siddha system of medicine is a holistic medicine to treated the individual 
as a whole and not the isolated case of the disease as found in modern medical 
science 
 
 Siddha medical science give importance to individual body constitution 
and customize the treatment based on humoural [MUKKUTRAM] pancha 
pootha concepts. 
 
The Vaidhyam (Treatment ) is also based upon five Properties of the 
drugs as suvai (Taste), Gunam (Character) Veeriyam ( potency) Private class 
Mahimai  (Action) 
 
 The plant kingdom has several thousands of species. Siddhar’s have 
Identified certain plants to posses medicinal properties and named as 
Mooligaikal. 
 
Nilavembu is one among them to cure more diseases especially - NEER 
PENISAM(Allergic Rhinitis)  
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Neer Peenisam  strongly  correlated with allergic rhinitis for its resemble 
of signs and symptoms approximately 2-6% of Indian  population are prevalent 
for this disease in which Bronchial asthma  seen in 50%  cases. Pharyngitis, 
otitis  media and deafness are as a result of sino nasal pathology. There is a 
need for holistic medicine of Indigenes origin. Which has to be effective non-
toxic affordable. Especially for those who suffering from allergic Rhinitis.  
 
This dissertation along with siddha perspective. Modern medical science 
have also been included to evaluate the efficacy of Nilavembu Chooranam to 
alleviate the disease Neer peenisam.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
AIM AND OBJECTIVES 
 
AIM  
To evaluate the efficacy of Nilavembu Chooranam ( Powder of 
Andrographis- paniculata) in the management of Neer peenisam. 
 
OBJECTIVES:  
A Systematic study to assess the efficacy of Nilavembu Chooranam was 
aimed and the main objectives of the study are : 
 
• To study the pharmocognostic features of  the Nilavembu 
(Andrographis- paniculata) which include correct taxonomic 
identification of the plant macro and microscopical details of  the part 
used as medicine. 
 
• To subject the Drug to physio –chemical Standardization. 
• To Identify the phyto chemicals present in NVC 
• To Subject the total drug to thin layer chromatography to determined. 
The RF Values.   
• To study the NVC to bio chemical analysis  
• To study the  acute  toxicity of NVS for fixation of  Therapeutic dosage.  
• To Study the Pharmacological activity of NVC.  
• To ascertain the clinical efficacy of the drug 
• MAPA - 2000 – 06  3342 V 22 Page 694. 
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REVIEW OF LETERATURE 
 
I. GUNAPADAM ASPECT 
 
epyNtk;G 
Botanical Name : Andrographis Paniculata (Burm. F) wall.ex.nees 
 
NtWngah;fs;  : rpul;Fr;rp> fhz;lfk;> fpuhjfk;> fphpahj;J>  
fpuhfjp ehl;LepyNtk;G> mdhjphpajpj;jk; 
fLepk;gk; fhz;lk;> Nfhfzk; nfhw;wpiy 
Nfhfejk; jpj;jk; Gepk;gk;. G+kpehafd;. 
 
,J xU rpW nrb> epyNtk;ghdJ 1½  mb ePskhfTk; ehd;F %iyfs; 
cs;sjhfTk; nfhQ;rk; fWg;ghfTk; ,Uf;Fk;. 
gad;gLk; cWg;G  : ,iy> jz;L. 
Fzk;  
Rit   : ifg;G  
jd;ik   : ntg;gk; 
gphpT   : fhh;g;G 
tPhpak;   : ntg;gk;. 
 
nra;iffs; :- 
grpj;jPj;J}z;b : Stomachic 
cukhf;fp  : Tonic 
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clw;Nwe;jp  : Alterative 
ntg;gKz;lhf;fp : Stimulant 
 
nghJ Fzk; :- 
  thj Ruk; ePNuw;wk; khw;Wr; RuNjhNl 
  fhjnkd Xlf; fbAq;fhz; - khjuNr! 
  gpj;j kaf;fDf;Fk; gpd;G njsp itf;nfhLf;Fk; 
  Rj;j epy Ntk;gpd; njhopy;. 
      (mfj;jpah; FzthRlk;) 
,jdhy; tspRuk; ePh;f;Nfhit, Ruq;fs;, kaf;fk; ,itfs; ePq;Fk; Gj;jpf;Fj; 
njspTz;lhFk;. 
tof;F Kiwfs; :- 
¾ epyNtk;G 15 fpuhk; nte;ePhpy; Nrh;j;J %b xU kzp Neuk; 
nrd;w gp;d; tbfl;b jpdk; 15 -30 k; yp msT 2-3 Kiw nfhLf;f 
ePhNfhit tsp Ruk; Ruq;fs; Nghd;w Neha;fSf;F 
nfhLf;fyhk; 
 
¾ ,jd; ,iyr;rhw;iwf; Foe;ijfl;Fz;lhFk; tapw;Wg; nghUkYf;Fk; , 
fopr;rYf;Fk; toq;fyhk;. 
 
epyNtk;G FbePh; 
1. epyNtk;Gr;r%k;   FbePh;  
2. ntl;b Nth;    30-60kpyp fpahok; 
3. tpyhkpr;rNth;   fhiy khiy 
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4. re;jdj; J}s;   ,UNtis 
5. Nga;g;Gly; r%yk;    
6. Nfhiuf; fpoq;F   
7. Rf;F     
8. kpsF    
9. gw;glhfk;.     
 
epyNtk;G NrUk; gpwkUe;Jfs;   jPUk; Neha;fs; 
 
1. FLr; ahjp f\hak; -  Fsph; Ruk;    
2. epyw;Fkpo; vz;nza;  -  cs khe;ij 
3. th]hjp f\hak;   -  Fsph; Ruk; 
4. Fl[hjp f\hak;   -  Ruk; 
5. rpW gQ;r %yf; f\hak;  -  rpj;j gpuk;k rd;jp 
6. Nfh\;lhjp f\hak;  -  fhrk; 
7. g+epk;; ghjp #uzk;   -  tprf;fha;r;ry; 
8. gpUfj; fpuhj ijyk;  -  tprf;fha;r;ry; 
9. rpw;w Kl;b FbePh;  -  tspKg;gpzp Ruk;  
10. fPh;guhj;JNt FbePh; -  Fsph; Ruk; 
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BOTANICAL ASPECTS 
ANDROGRAPHIS PANICULATA (BURM –F) WALL EX NEES . 
SYN: JUSTICIA PANICULATA- BURM.F 
TAXONAMY 
 
KINGDOM - PLANT KINGDOM. 
DIVISION  - ANGLOSPERM 
CLASS  - DICOTYLEDONE. 
SUBCLASS - GAMOPETALAE. 
SERIES  - BICARPELLATAE. 
ORDER  - PERSONALES. 
TRIBE  - JUSTCIEAE. 
FAMILY  - ACANTHACEAE. 
GENUS  - ANDROGRAPHIS. 
SPECIES  - PANICULATA. 
 
VERNACULAR NAMES 
HINDI - KIRYAT, CHARAYETAH, MAHATITA  
BENG  -  KALMEGH, MAHATITA 
GUJ   - KIRYATA, OLIKIRYATO, KARIYATU 
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KAN   - NELA- BEVINAGIDA, KREATA, NELABERU 
MAL   - NELA- VEMBU, SHIRAT KUCHCHI 
TEL   - NELA VENNU 
ARAB  - OASABUZZARIAH, QASABHUVA 
ORIYA  - BHUINIMBA 
PERS  - NAINE HAVAND 
SING   - NIN-BIN KOHOMBA 
 
ANDROGRAPHIS PANICULATA 
PHARMACOGNOSY 
Macroscopic 
An erect glabrous, Annual , much branched herb up to 90 cm high, branched 
sharply quadrangular. Often narrowly winged in the upper part. Leaves simple 
opposite, short – petiole, 2-7 cm long and 1-3 cm wide, lance late, glabrous, 
slightly undulate, pale beneath base tapering, main nerves 4-6 pairs, slender; 
petioles 0-6 mm long . Flowers pink on solitary , auxiliary and terminal 
panicles. Capsules erect, linear – oblong, compressed, longitudinally furrowed 
on the broad faces, thinly glandular hairy; seeds numerous, sub-quadrate. 
Leaf 
Both the upper and lower epidermii show the presence of glandular trichomes. 
Lithocysts fairly large on upper epidermis as compared to the lower. Lower 
epidermis has a layer of wavy walled cells and diacytic type of stomata, which 
is absent on the upper surface. 
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STEM                                                  
Epidermis has glandular and non-glandular trichomes. Collenchya densely 
found at the corners of the stem. Secondary phloem consists of acicular fibre 
mainly. Xylem fibre are elongated and thickened. Vessels with scalariform and 
spiral thickenings. Parenchyma cells of the pith contain small acicular crystals 
of calcium oxalate. 
 
CHEMICAL CONSTITUENTS 
Andrographolide, a furanoid diterpene (leaves, root, whole plant); 2’5- 
dihydroxy 7,8- dimethoxy flavone 2’-0 beta (D)- glucoside,3 B-hydroxy -5 
stigmasta 9 ( 11) , 22(23)-diene, andrographin, glycoside–neoandrographolide, 
flavone -5 hydroxy – 7,8,2’,3’-tetramethoxcyflavone,5-hydroxy- 7,8 flavanone, 
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a-sitosterol, apigenin, Mono-oxymethlyl- wigthin, 5 hydroxy 7,8 dimathoxy 
dimethoxy flovone, 5-hydroxy 3,7,8,2 tetramethoxy flavone 7-0 methrlwoconin 
, apigenin – 7-4’ – di-o-methy, ethe,r flavone glucosides, Andro graphidines, 
A,B,C,D,E & F (root); -B-sitosterol glucoside, bitter substances, 
deoxyandrographolide – 19-B glucoside, neoandrographolide, caffeic  
chlorogenic , dicaffeoylquinic acids, panicolide, myristic acid, carvacrol, 
eugenol, hentriacontane, tritricontane, andrographone, horroandrographolide, a-
b unsaturated lacton (leaves), andrograpanin. 
 
ADULTERANTS / SUBSTITUTES  
The  drug s often substituted for or mixed with the genuine ‘Chirata’ [swertia 
chirayita] ( Roxb. Ex. Fleming) Karst.] but can be distinguished from the latter 
easily by the green colour  of its stem , numerous erect, slender, opposite 
branched and its lanceolate green leaves . kalmegh is also adulterated with 
andrographis echioides Nees. Found in tropical India and in dry districts of 
maharashtra, rajasthan, and tamil nadu. However, both swertia chirayita and  
Andrographis echioides are  devoid andrographolide, the major bioactive 
constituent of kalmegh 
 
SAFETY ASPECTS 
Gastric discomfort, vomiting and loss of appetite may be caused by the large 
oral doses of the drug. Injection of the crude drug extract may lead to 
anaphylactic shock.  
 
PHARMACOLOGY: 
Andrographolide and related diterpenes are hepatoprotective agents. These 
compounds also possess choleretic,antidiarrhoeal, immunostimulant,bitter tonic, 
febrifuge and anti-inflammatory activities 
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TLC IDENTITY TEST 
Test solution :  Extract 5g of powdered drug  with methanol (50ml) in a soxhlet 
apparatus (6hr). Evaporate the methanol extract under reduced pressure. 
Dissolve 10mg of residue in 1 ml methanol. 
 
Reference solution: Prepare a solution containing 1mg each of 
andrographolide,  neoandrographolide and andrographiside in 1.5. ml methanol. 
 
Solvent System: Chloroform : Methanol (7:1) 
Procedure: Apply 5 μl each of test solution and reference solution on two 
different tracks on a precoated silica gel 60 plate (5x20 cms) of uniform 
thickness (0.2 mm). Develop the plate in the solvent system to a distance of 15 
cm 
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Scanning:  scan densitometrically at 223 nm both reference and test solution 
trcks and record the fingerprint profiles. Quantitation of androgropholide,  
neoandrographolid and  andrographiside in the test solution can be done by 
comparing their peak areas with those  present in the reference solution track. 
 
Visualization of spots (post scanning) : spray the plate with 20% sulfuric acid in 
methanol and heat at 120◦ C for 10 min. 
 
Evaluation : in day light: Three different spots visible in reference solution: 
andrographolide (Rf 0.70, brown) ,neoandrographolide ( Rf 0.39, pink ) and  
andrographiside ( rf 0.12, Violet) and their corresponding spots in test solution.  
Other visible spots in the test solution include a light violet spot (Rf. 0.23), a 
light brown spot just below the spot corresponding to  andrographiside , and an 
unmoved dark green spot at the base. 
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ASSAY / ANALYTICAL METHOD 
HPLC Analysis of andrographolide – the major bio- active constituent 
Mobile phase : Chloroform : Methanol ( 9:1) 
Flow rate   : 0.7 ml / min 
Column   : 5 μm spherical silica (3.0 mm x 15 cm )  
Detector   : UV at 254 nm 
 
Standard Preparation : Prepare a solution of known concentration ( conc. 
Rang: 05-10 mg/ml) of andrographolide in mobile phase. 
 
Sample Preparation :  Extract exhaustively – ( 5hr ) known quantity of 
powdered drug (10g) in a soxhlet apparatus with methanol. Evaporate the 
Extract to dryness, dissolve and make-up the volume to a known strength 
(50μg/ml). Prepare further dilutions in mobile phase, if necessary. 
 
Procedure:  subject know volumes (10μl) of standard and sample preparations 
to HPCL and record the respective peak area for andrographolide in triplicate 
and accordingly calculate its percentage in the sample. 
 
 
 
 15
 
 
QUANTITATIVE STANDARDATION 
 
Foreign organic matter   : Not more then 2.0% 
 
Ash      : Not more than 15.0% 
 
Acid insoluble ash    :  Not more than 3.0% 
 
Alcohol soluble extractive  : Not more than 8.0% 
 
Alcohol (60%) soluble extractive : Not more than 24.0% 
 
Water soluble Extractive   : Not more than 20.0% 
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THERAPEUTIC EVALUATION 
 
1. A double blind study with a new mono drug. KAN JAN(Andrographis 
Paniculata) in a dose of 1200 mg/day has been reported to significantly 
shorter the course and duration of the disease and is indicated for an 
enhanced residence to common- cold.  
MAPA- 9604 – 2072. V18- 4 1996 Page 383. 
 
2. Oral administration of Andrographolide isolated from. A.Paniculata 
Leaves. Andrographolide.  Showed significant (P value Less than 0.05) 
analgesic activity in acitic acid induced writing in mice. 
Andrographolide (100 and 300mg 1 kg oral) produced significant (P less 
than 0.05) Anti pyretic effect. After 3 hrs of administration in. Brewers – 
yeast induced pyrexia in rates. 
Andrographolide  also exhibited significant (P Less than 0.05)  anti 
ulcerogenic- activity at 100 and 300 mg/kg doses aspirin induced 
ulceration in rates. Pharmaceuticals science v-57(3) Pare 121-125-1995 
 
3. Andrographolide a diterpene Lactone isolated from the A.Paniculata after 
oral administration at doses of 30, 100 and 300 mg 1 kg. significantly 
inhibited carrageenin induced paw edema the anti-inflammatory activity 
of andrographolide decreaeased edema in adjuvant induced arthritis. 
Fitoterapia v . 6705)     Page 452 – 458 1996 (Eng 14 Ref) 
 
4. The A.Paniculata drug might have the cell membrane. Stability property 
which may lead to prevention of the toxic effect of bile salts in various 
hepatic disorders. 
MAPA- 2062  03 – 1662  v. 24 page 392. 
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5. Antimicrobial activity in vitro ant filarial effect of A.Paniculata Species 
against adult worm of sub Bragia Malayi.  
MAPA -2002  03-17-07 v.24 page 400. 
 
6. The History of using plant based herbal drugs in India is about . 7000 
years old using herbal. drugs (A.Paniculata) as effective as synthetic 
drugs for quick relief and permanent cure of in curable disease.   
MAPA- 2002 – 04  2118  volume-24 page 506   
 
7. A.Paniculata commonly known as king of bitter – which has large 
importance to the mankind for its therapeutic and much other potential .   
MAPA -   2004 – 05 – 2322 volume-26 page 538. 
 
8. Aqueous extract showed significant anti microbial activity which may be 
due the combined effect of the isolated Arabinogalactin  proteins and 
Andrographolide.  
 MAPA- 2004. 20839 V.26 – Page 187 
 
9. The data found in the Spontaneous reporting scheme of WHO and 
Natural drug safety bodies, the data suggested that A.Paniculata is 
superior to placebo in alleviating the subjective symptoms of 
uncomplicated URI.  There is also preliminary evidence of a preventative 
effect.  
MAPA- 2004  - 1610 Volume- 26; Page 378. 
10. A Phase of one trial of Andrographolide in HIV-1 Patients and Normal 
Volunteers leading to rise in CD4 Lymphocyte Level in HIV infected 
individuals. 
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Review and literature  
ePh;g;gPdprk; 
NtW ngah;fs; 
 
gPdprk; > ePh;f;Nfhit ,%f;FePh;gha;jy;  
 
,ay; : - 
 %f;fpd; Jisfs; rpte;J> Jk;ky; fz; rpte;J ePh;tbjy; ,%f;fpy; 
ePhgha;jy;, jiy Nehjy; mbfb %f;if rpe;jp ePh; tUjy; vd ,ay;GilaJ. 
 
%f;fpy; cz;lhFk; Neha;fs; 86 ,tw;wpy; gPdpj;jpd; fPo; 9 
tifahf tifgLj;jp ePh; gPd;rk; xd;whf tifg;gLj;jgl;Ls;sJ 
 
Neha; tuf;fhuzq;fs;:- 
1. kpfTk; Fsph;e;j ePiu gUFjy; 
2. gdp my;yJ Fsph;e;j fhw;wpy;  <Lgly; 
3. G*jp $ba fhw;W Jk;kiy cz;lhf;f $ba nghUs;fis Kfh;tjhYk;  
4. Iaj;ij ngUf;f $ba Fsph;e;j ePhpy; jiy %o;Fjy; 
5. Fsph;r;rp jUk; nghUs;fis cl;nfhs;Sjy; 
6. gjpdhW Ntfq;fis rhh;e;j fz;zPh; the;jp ,tw;iw mlf;FtjhYk; 
7. msTf;F kpUe;jhtJ Fiwe;jhtJ J}f;fk; nfhs;tjhYk; gPdpr 
Neha; Vw;gLk;.  
8. xt;th kz%l;L nghUl;fs; Efh;jy;.                                                            
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gpdprj;jpd; nghJ Fzq;fs;:- 
 
“jiykpf typf;Fk; ehrp rsptpo nkhLTz;lhFk;  
 eypWT Jk;kYz;lhFk; ehl;nrypy; twS ehrp  
 kiyTwj; jpuz;L tpOk; thANk ehw;wKz;lhk;  
 ngy Kw %f;filf;Fk; gPspr nkd;Nw NjNu”                               
 
ePh; gPdprj;jpd; Fzk;:>- 
 
 “fz;lNkd; Kfq;fz; fhJ fufuj; J}h;t NjNghy;  
 Jz;l Nkd; wpdT gw;wpr; nrhhpe;J}jd; ryKk; tPo;e;J  
 kz;ilAq; fdj;J nehe;J typkpf TsNj ahfpy;  
 gz;LNrh; %f;fpdphpg; gha;r;rhyd; Wiuf;f yhNk” 
 
 
%f;fpd; ntspGwj;jpy; ePh; Xbf;nfhz;bUg;gpd; mjid 
Kz;zPh;g;gha;r;rnydTk; (Rhinorrhoea) njhz;ilapDk; Gwj;Nj ePh; 
ngFjp thapd; top th;d gpd; ePh; gha;r;rnydTk; $Wth; (Post Nasal 
Drip)  
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FwpFzq;fs; :- 
 
1. %f;filg;G Nasal blook  
2. %f;fpy; ePh; gha;jy;  (Rhinorrhoea) 
3. %f;FePh; njspthf fhzg;gly; (Watery discharge) 
4. jiy Neha;; (Headache) 
5. Ruk; (Feverish) 
6. cly; Nrhk;gy;  (Malise) 
7. if fhy; Nehjy; (Body Pain) 
 
Kf;Fw;wk; :- 
 
czT Kjypa nray;fshy; cly; ntg;gkile;J moy;  Fw;wk; kpFe;J 
NghJ [ae;ijg; ngUff;$ba nray;fshy; gpwe;j [ak; moNyhL 
$bg;gpwe;j NehahUk; 
 
ehb:- 
  
gz;ghz  gpj;jj;jpy; Nrj;Jkk; $b 
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              ghprpj;jhy; gPdprKk;. 
       rjf ehb   
  
 
 
 
MATERIALS  AND  METHODS 
 
PREPARATION OF THE NILAVEMBU CHOORANAM 
 
The Drug “Nilavembu” was taken from the ‘Agastiyar Gunavagadam’ found in 
Siddha text book Gunapadam mooligai (siddha Mederia Medica Medicinal 
plants division) written  by Dr. Murugesa mudaliyar . 
 
COLLECTION OF THE TEST DRUG 
 
Nilavembu- [Andrographis Paniculata ]  Plants were collected from agricultural 
land at Vandavasi Tiruvannamalai District. The identity was conformed by 
Dr.SasikalaEthirajalu Botanist CRI for siddha Chennai 600 106. with the help 
of pharmacojnostic study. 
 
PROCEDURE :- 
 
The Fresh plants were washed well inthe running  water to remove the 
impurities then the plants were cut into pieces and dried in shade. After drying  
they were finely powdered to obtain the medicine in its finest physical form the 
powder is sieved through a white cloth. [VASTHARAKAYAM]   
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PURIFICATION OF THE CHOORANAM 
 
The powder was moistened with cow’s milk . The pot was half filled with milk 
and water the mouth of the pot was covered and tied with while cotton cloth the 
chooranam ( moistened by milk ) was placed above. The tied cloth the mouth of 
the pot closed with another mud pot. The gap between the two mud pots was 
tied  with a wet cloth to avoid evaporation, then this arrangement was put on 
fire and boiled until water level gets reduced in the lower pot, then the  powder 
was taken dried powdered finally and preserved for usage. 
 
STORAGE OF THE CHOORANAM 
 
The chooranam was stored in a clean air tight glass container . The life period 
of the chooranam is three month the prepared chooranam was used within the 
period. 
 
ADMINISTRATION OF THE DRUG 
 
FORM OF 
THE 
MEDICINE 
ROUTE 
DOSE 
 
TIME OF 
ADMINISTRATIVE
 
VEHICLE 
 
Chooranam  Enternal 
1 g two 
times/day 
After food 
Hot water 
{about 30 
ml} 
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The prepared Nilavembu chooranam was done subjected to various analyses 
and the methodology followed is given. 
 
TOXICITY STUDY 
 
1.1 Test Drugs 
 
 The following medicinal plants were used in the study were collected and 
processed by the methods prescribed in standard text books of siddha 
medicines. 
 
1.1 Nilavembu Chooranam [ NVC] 
NVC was prepared by the method described in Gunapadam Mooligai- 
Vaguppu .   page no : 579-80) 
 
1.2 Preparation of drug for dosing 
 
 All drugs used for the study was suspended each time with 1% (w/v) 
solution of sodium car boxy methyl cellulose before administration. 
 
1.3 Drugs and chemicals 
 
 Histamine hydrochloride and fine chemicals used in these experiments 
were obtained from Sigma Chemicals company, U.S.A. Other analytical grade 
chemicals were obtained from S.d. Fine Chemicals Ltd., Mumbai. 
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1.4 Experimental animals  
 
 Colony inbred animals strains of Wister rats of either sex weighing 200 - 
250 g were used for the pharmacological and toxicological studies. The animals 
were kept under standard conditions 12:12 (day/night cycles) at 220C room 
temperature, in polypropylene cages. The animals were fed on standard 
palliated diet (Hindustan Lever Pvt Ltd., Bangalore) and tap water ad libitum. 
The animals were housed for one week in polypropylene cages prior to the 
experiments to acclimatize to laboratory conditions. The experimental protocol 
was approved by the Institutional Animal Ethical Committee (IAEC). 
 
1.5. Acute oral toxicity study.     
 
Acute oral toxicity was conducted as per the OECD guidelines 
(Organization of Economic Cooperation and Development) 423 (Acute Toxic 
Class Method). The acute toxic class method is a stepwise procedure with 3 
animals of a single sex per step. Depending on the mortality and /or moribund 
status of the animals, on the average 2-4 steps may be necessary to allow 
judgment on the acute toxicity of the test substance. This procedure results in 
the use of a minimal number of animals while allowing for acceptable data 
based scientific conclusion. 
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The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) 
and the results allow a substance to be ranked and classified according to the 
Globally Harmonized System (GHS) for the classification of chemicals which 
cause acute toxicity. 
Wistar albino rats of either sex weighing 200-250 g were fasted 
overnight, but allowed water ad libitum. Since the formulation is relatively non 
toxic in clinical practice the highest dose of 2000 mg/kg/p.o (as per OECD 
guidelines “Unclassified”) was used in the acute toxicity study.   
 
The animals were observed closely for behavioral toxicity, if any by 
using FOB (Functional observation battery). 
 
1.6 Repeated oral toxicity study  
Repeated oral toxicity studies can be used to get additional information 
regarding the toxicity profile of a chemical. Repeated oral toxicity studies are 
defined as those studies where the chemical is administered to the animal for a 
period covering approximately 10% of the expected life of the animal.  
Usually, the dose levels are lower than for acute studies and allow 
chemicals to accumulate in the body before lethality occurs, if the chemical 
possess this ability. 
1.8 Experimental procedure 
The following experimental procedure was followed to evaluate the 
repeated oral toxicity study of: 
Nila Vembu Extract (NVE)  
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Group I  :      Control animals received 1% Sodium carboxy methyl cellulose 
(CMC), 2   ml/kg/p.o. for 21 days  
Group II : Drugs suspended in CMC was given at the dose Level of 
500 mg/kg/p.o.  for 21 days 
 Body weight, food intake and water intake was recorded at two intervals 
with simultaneous observation for toxic manifestation and mortality, if any. At 
the end of 21 days treatment all the animals were sacrificed by over dosage of 
ether anesthesia. Blood was collected and used for hematological studies. 
Section of liver, kidney, and heart were dissected out and kept in 10% formalin 
for histopathological studies. 
RESULT 
 
Acute oral toxicity study 
 
NVE at the dose of 2000mg/kg/po did not exhibit any mortality in rats. 
As per OECD 423 guidelines the dose is said to be “Unclassified” under the 
toxicity scale. Hence further study with higher doses was not executed.  
 
Repeated oral toxicity for 21 days 
 
Test drug NVE  at the dose of 500 mg/kg/po when administered orally 
for 21 days in rats did not show toxicity in renal functions. There was an 
significant increase in % of Hb and RBC                (Table 2 ). However the drug 
did not show any significant elevation of marker enzyme levels of liver              
(Table 3). 
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Table 1 
Effect of Siddha Formulations (NVE) on Hematological parameters after 
15 days repeated oral dosing (500 mg/kg) 
Group
s 
Hb 
(gm/100m
l) 
RBC 
(millions/
cu.mm) 
WBC 
(cells/cu.mm
) 
Differential leucocyte count (%) 
Lympho 
cytes 
Mono 
cytes 
Granulo
cytes 
Normal 13.08 ± 
0.34 
4.31 ± 
0.35  
54850 ± 9.44 76.06 ± 
3.89  
5.30 ± 
1.04 
16.50 ±  
4.27 
NVE 
(500m
g/kg/p.
o) 
13.68 ± 
0.70 ns 
4.68 ± 
0.72 ns 
5786.66 ± 
3.323 
77.67 ± 
3.32 ns 
8.16 ± 1.7 
ns  
16.66 ± 
3.44 ns 
 
n=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
ns – non significant when compared to control groups  
 
Table 2 
Effect of Siddha formulation (NVE) on Biochemical markers of liver and 
kidney after 15 days repeated oral dosing (500 mg/kg/po) in rats  
Groups ALP 
(K.A.Units) 
AST  
(IU/L) 
ALT  
(IU/L) 
Urea 
(mg/100ml) 
BUN 
(mg/ 100ml) 
Normal 3.78±0.38 78.48±0.23  28.70 ± 
0.81 
13.56 ± 0.37 6.48 ± 0.50 
NVE 
(500mg/kg/p.o) 
4.32±0.75ns 79.55±5.92 30.13 ± 14.60 ± 0.69 7.51 ± 0.35 ns
 28
ns 2.67 ns ns 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
Ns – non significant when compared to control groups  
ANALGESIC ACTIVITY 
TAIL FLICK   METHOD 
 Withdrawal of tail (Tail Flick) for noxious thermal (radiant heat) can 
be used for screening Neelavembu Chooranam with analgesic activity. 
Radiant heat can be generated by passing electrical current through nichrome 
wire mounted in an analgesiometer. 
  The base of the tail of the test rats is placed on a nicrome wire. The 
tail withdrawal for the radiant heat (flicking response) is taken as the end point. 
Normally the rats and mice withdraw their tails within 3 – 5 secs. A cutoff time 
of 10 – 12 secs is used to prevent damage to the tail. Any animal failing to 
withdraw its tail in 3-5 secs is rejected from the study.  
 The reaction time of test drug, standard and control are taken at intervals 
of 30, 60 and 120 mts. A reaction time (withdrawal time) increment of 2-5 secs 
more than the control animals can be considered for analgesic activity of the 
drug.  
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Table 3 
Analgesic activity of NVE  using Tail flick  Method 
Groups Paw licking response  (Sec) 
0 min 
( Sec) 
30 min 
( Sec ) 
60 min 
(Sec ) 
120 min 
(Sec) 
Control 1.56 ±  
0.96 
1.86 ± 
 0.96 
1.76 ± 
 0.67 
1.86 ±  
0.53 
 
Test 
(500mg/kg. 
p.o.,) 
1.86 ±  
 0.206 
ns 
3.133 ± 
0.258 
*** 
4.966 ± 
0.516 
*** 
5.15 ± 
1.394 
*** 
 
                             n=6,  Values are expressed as mean ± S.D using followed  
                             by student paired T – test , ns- non significance 
                                            ***P<0.001 as compared with control.  
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ANTI - INFLAMMATORY  ACTIVITY 
 Anti inflammatory activity was evaluated in acute model of 
inflammation. 
Acute model 
Carrageenan induced hind paw edema  
 The carrageenan assay procedure was carried out according to the 
method of Wintar et al. (1962). Edema was induced by injecting 0.1 ml of 1% 
solution of carrageenan in saline into the plantar aponeurosis of the left hind 
paw of the rats.  The extracts, reference drug and the control vehicle (distilled 
water) were administered 60 min prior to the injection of the carrageenan. The 
volumes of edema of the injected and contra lateral paws were measured at +1, 
3 and 5 hrs after induction of inflammation using a plethysmometer (Bhatt et 
al., 1977) and percentage of  anti-inflammatory activity was calculated.                                                           
Table 4 
          Anti inflammatory activity of  NVE induced end paw     
                                      edema in rats 
Groups Paw volume ( ml) by mercury Displacement 
at regular interval of time 
0min 30min 60min 120min 240min 15 hrs 
Control 
 
1.233 ± 
0.338 
1.733± 
0..225 
2.066± 
0.286 
2.200 ± 
0.236 
2.25 ± 
0.273 
2.266± 
0.236 
NVE 
(500mg/kg. 
p.o.,) 
1.233 ± 
0.338 
ns 
1.40 ± 
0.236 
ns 
2.03 ± 
0.2366 
ns 
1.566± 
0.316 
*** 
1.533 ± 
0.372 
*** 
1.491 ± 
0.174 
*** 
Standard 
(Dic.Sodium 
5 mg/kg/po) 
0.835 ± 
0.065 ns 
1.315 ± 
0.069ns 
1.128 ± 
0.049*** 
1.011 ± 
0.056***
0.896 ± 
0.048*** 
0. 85 ± 
0.054 
*** 
             n=6; Values are expressed as mean ± S.D followed by student  
             paired T- test. 
             ns - Non significant as compared with control; 
             P< 0.001 (***) as compared with control. 
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HISTAMAINE  STUDY 
Antagonistic action of PC in Guinea pig ileum contraction.  
 
Histamine is an autocoid having many physiological effects in the 
system. Histamine has spasmogenic response in g.pig ilium. Histamine by 
acting on H1 receptor of smooth muscle causes contraction which can be 
recorded by a kymograph. Drugs  acting as H1 receptor antagonists, block the 
contraction of histamine in g.pig ileum. 
 
G.pig ileum is dissected out and placed in the watch glass containing 
Tyrode solution. Dissect out the ileum and clean the contents of the ileum by 
pushing the Tyrode solution into the lumen of the ileum. 
 
2 – 3 cm long ileum is taken and mounted to the tissue holder of the 
organ bath containing Tyrode solution maintained at 32 – 340C and bubbled 
with a mixture of CO2 + air.  
 
A tension of 0.5 g is applied to the lever and the tissue is allowed to 
equilibrate for 30 mts before adding drugs. Record concentration dependent 
response (10 μg – 80μg) due to histamine using a frontal writing lever. Add the 
test drug in different concentrations (2 μg - 5μg) to the tissue bath and repeat 
the concentration- response curve of histamine in the presence of the test drug. 
Calculate the % inhibition of contraction by the test drug.  
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Histamines activity - showed in chymograph  
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Table 5 
Effect of the NVE  on histamine induced contractions of guinea pig ileum 
S.No 
Treatment 
Histamine 
μg/ml 
Mean 
contractio
n 
(M meter) 
NVE 
μg/ml
Mean 
contraction 
M meter 
% inhibition 
of Histamine 
1. 10.0 
25.62 ± 
0.322 
10.0 
10.08± 0147 
*** 
40.0 
 
2. 20.0 
54.0 ± 
0.672 
20.0 
37.33 ± 0.216
*** 
68.5 
 
3. 40.0 
66.130 ± 
0.271 
40.0 
47.5 ± 3.216 
*** 
 
71.5 
 
4. 80.0 
75.0 ± 
0.546 
80.0 
54.60 ± 0.967
*** 
72.0 
 
    n=6; Values are expressed as mean ± S.D followed by Students      
                                  Paired ‘T’ Test 
                                                 P<0.001 as compared with that of control. 
RESULTS 
Analgesic, Anti inflammatory and Anti histaminic studies  
Nila Vembu Extract (NVE) is used in the Siddha system of medicine for 
its anti allergic activity. In the present study NVE showed antagonistic action 
against Histamine induced contractions in guinea pig ileum. Histamine assay in 
g.pig ileum is used to evaluate the antihistaminic activity of drugs acting on H1 
receptors. NVE showed a dose dependent reduction in the height of contraction 
for histamine in g.pig ileum. NVE also exhibited antiperoxide and antioxidant 
activity against oxygen free radicals. 
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ANTI MICROBIAL  STUDY 
 
 Paper disc diffusion method 
The sterilized (autoclaved at 120 o C for 30 min ) medium ( 40-50 o 
C ) was inoculated ( 1 ml / 100 ml of medium ) with the suspension ( 10 5 cfu 
mL -1 ) of the microorganism ( matched to Mc Farland  barium sulphate 
standard ) and poured in to a petridish to give depth of 3-4 mm. The paper 
impregnated with the test compounds ( 25, 50, and 100 µg mL-1in dimethyl 
farmamide ) was placed on the solidified medium. The plates were pre 
incupated for 1 h at RT and incupbated at 37o C for 24 and 48 h for anti 
bacterial and anti fungal activities, respectively. Ciprofloxin ( 100 μg /10 disc ) 
and ketoconozole ( 100 µg/ disc ) were used as standard for anti bacterial and 
anti fungal activities, respectively. The observed zone of inhibition is presented 
in table In-vitro antimicrobial activity of NVE as screened against bacteria and 
yeast strains. The results are depicted in Table 6. In 10 μl/disc concentration of 
NVE were exhibited  low antibacterial activity in streptococcus mutans and 
aereus. others were exhibited moderate to high antibacterial activity when 
compared to standard drugs ciprofloxacin and ketoconozole respectively. 
 
Table 6 
Zone of inhibition in mm 
Organism Standard 
drug 
Ciprofloxacin 
50 mcg/disc 
Test drug (NVEµl/disc) 
Zone of inhibition in mm 
10μl 25μl 50μl 
Strep. Mutans 30 15 19 22 
Staph. Aureus 31 13 16 19 
E.coli 31 12 18 22 
K.pneumoniae 30 11 14 19 
Ps.areginosa 31 13 16 19 
In vitro anti microble activity of Nilavembu Chooranam extract showed that 
the drug was sensitive to Streptococcus Mutans staphylococcus Aureus and 
resistant to K. pneumoniae 
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ANTIOXIDANT STUDY 
 
In Vivo Antioxidant study 
Samples of serum collected from  rats treated with test drugs were 
assayed for GSH (Moron et al , 1979)  and LPO (Yagi, 1976)  and the results 
were compared with  control group.  
Table 7 
Anti oxidant activity of Siddha Formulation (NVE )  
after 15 days repeated oral dosing (500 mg/kg) 
Groups LPO GSH 
 
Control 0.63 ± 1.37 46.28 ± 2.31 
 
NVE 
(500mg/kg/p.o) 
0.42 ± 3.90*** 83.31 ± 0.35*** 
 
N=6; Values are expressed as mean ± S.D followed by Student T- Test. 
***P<0.001 as compared with control.  
Antioxidant activity  
At the end of 21 days repeated oral toxicity study when the plasma of 
drug treated animals was examined for GSH activity, the level of GSH activity 
was increased significantly (p>0.001) in test groups. On the other hand the LPO 
activity was considerably reduced in drug treated group when compared to 
control. 
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QUALITATIVE ANALYSIS OF ACIDIC/BASIC RADICALS AND  
BIO-CHEMICAL CONSTITUENTS IN TEST DRUGS 
Procedure Observation inference 
Test for Calcium : 2 ml of 
extract is taken in a clean test 
tube. To this add 2 ml of  4% 
ammonium oxide solution.   
white precipitate is formed Presents of calcium  
Test for Sulphate : 2 ml of the 
extract is added to 5 % barium 
chloride solution. 
 white precipitate is formed  Presents of Sulphate  
Test for Chloride : The extract 
is treated with Silver nitrate 
solution  
 white precipitate is formed Presents of Chloride 
Test for carbonate : The 
substance is treated with Conc. 
HCl. 
 effervescence is formed  Presents of carbonate 
Test for Starch : The extract is 
added with weak iodine solution  
Blue colour is formed Presence of starch  
Test for Iron (Ferric) : The 
extract is treated with glacial 
acetic acid and potassium 
ferrocyanide  
 blue colour is formed Presents of Ferric iron 
Test for Iron (Ferrous) : The 
extract is treated with Conc. 
HNO3 and ammonium 
thiocynate 
No Blood red colour is formed Absence of Ferrous iron 
Test for phosphate : The 
extract is treated with 
ammonium molybdate and 
conc. HNO3 
Yellow precipitate is formed Presence of phosphate 
Test for Tannic acid : The 
extract is treated with Ferric 
chloride  
Blue black precipitate is 
formed 
Presence of Tannic acid 
Test for Unsaturation : 1 ml of 
Potassium permanganate 
solution is added to the extract.    
 get decolourised  Presents of unsaturated 
compound 
Test for saponins: Dilute 
extract+ 1ml of distilled water 
shake well. 
No Froth formation presence of saponins 
Test for sugars :  
 Benedict method ; 5ml of  
Benedict solution heated gently 
then add 8 drops of diluted 
extract then heated in a boiling 
water bath. 
 
No colour change 
 
 
 
    
 
  
Indicates the Presents of 
sugar 
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Molisch test; Dilute extract+2 
drops of Molisch+3ml 
conc.H2SO4. 
No Reddish violet zones 
appeared 
Absence of carbohydrate 
Test for steroids : Liberman 
Burchard test ; Dilute extract +2 
ml acetic 
anhydride+conc.H2SO4 . 
 Formation of red colour  Presences of steroids 
Test for amino acids: Dilute 
extract +2ml of Ninhydrin’s 
soln . 
Formation of  violet colour Presents of  amino acids 
Test for proteins: Biuret 
method ; 1ml of dilute 
extract+1mlof5%CuSO4+ 
1%NaOH. 
Formation of Violet   colour Presence of proteins 
Test for Flavanoids : Dilute 
extract+ mg  bits+2drops of 
conc.HCl  and gently heated. 
No formation of pink colour Absence of Flavanoids 
Test for phenol; Dilute 
extract+2drops of FeCl3 soln. 
 Deep green colour is formed Presence of phenols 
Test for Tannins ; dilute 
extract +2ml of 10%lead acetate 
add. 
White precipitate formed Presence of tannins 
Test for alkaloids; 
 Mayer’s method;1ml of dilute 
extract + 1ml reagent. 
 
Dragendroff’s method; 1ml of 
dilute extract+ 1ml of reagent. 
 
Appearance of cream colour 
precipitate 
 
 
 
Appearance of orange colour 
precipitate 
 
Presence of alkaloids 
 
 
 
Presence of alkaloids 
Result : 
 
 From the biochemical analysis the following chemical were. Found to be 
present in the test drug (NVE) 
• Acid Radicals         
 Sulphate 
 Phosphate 
 Chloride 
                  
• Basic Radicals 
 Calcium 
 Iron 
 Potassium 
 Magnesium 
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CLINICAL  ASSESSMENT 
 
STUDY DESIGN 
1. Open clinical trial  
2. Parameters for Evaluation . 
 
SYMPTOMS 
1. Thummal   [ Sneezing ] 
2. Mookil Neer Paithal [ Rhinorrhoea ] 
3. Namaichal   [ Itching Nose, Exes Throat ] 
4. Mokadaippu   [ Nasal Block ] 
5. Thalai vali   [ Headache ] 
 
LINE OF TREATMENT 
a. Does 500 mg bid = Hot water 
b. Root of administration. Enternal 
c. Duration : 45 days 
SELECTION  OF PATIENTS  
Sample size – 30 patients 30 patients are selected on the basis of the 
inclusion and exclusion criteria 
Inclusion      Exclusion 
1.   Signs and  symptoms of Neerpenisam  1  Acute  Phase of BA 
2. Age Between 15 – 60 yrs from age sex     2.  Patient Who have RVF / CCF 
                                                                              3.  Patient Who have any other        
                                                                         uncommitant illness  
                                                                   4.  Patient With  known liver or          
                                                                                   kidney disorders  
                                                                      5.  Patient having  hyperpyrexia. 
 40
WITHDRAWAL CREITERIA 
1. Irregular treatment  
To prevent with drawl of study medicine. Was given to each patients for 
a period of 15 days. 
 
 INVESTIGATION 
  Blood investigation  including HB% and TLC (Total  Leucocytes 
Count ) Raised Eosin Phil count on differential court suggested allergic 
with the body   65% had raised Eosin Phil count  
 
X RAY: 
Hypertrophied mucous of nose and Para nasal sinuses (PNS)  Indicate 
allergic causes with the nose  and  PNS.. 
 
DIAGNOSIS was based mainly on history of neer peenism symptoms and 
also by considering the demonstration of allergy on blood investigation and 
nasal smear or by x-ray investigation statistical analysis of treatment is 
recorded and tabulated as follows. 
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No of Patient
16-25
26-35
36-55
Table 8 
 
AGE WISE DISTRIBUTION 
 
S/no Age in 
years  
No of 
Patient 
Percentage
1 16-25 16 53.4 
2 26-35 6 20 
3 36-55 8 26.6 
 Total 30 100 
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SOCIO-ECONOMIC STATUS
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Table 9 
 
SOCIO-ECONOMIC STATUS 
 
 
S/no  Eco Status No of Patient Percentage 
1 Poor 8 26.7 
2 Middle 21 70 
3 Rich 1 3.3 
 Total 30 100 
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Table 10 
 
DIET 
 
S/no Diet No of Patient Percentage 
1 Vegetarian 4 13.4 
2 Mixed – diet 26 86.6 
 Total 30 100 
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Table 11 
 
OCCUPTION STATUS 
 
S.no Occupation No of Patient 
Percentage 
(%) 
1. Daily Labour 10 33.4 
2. House Wife 7 23.4 
3. Office Worker 3 10 
4. Auto Mobile 5 16.6 
5. Sales Rep. 3 10 
6. Students 2 6.6 
 Total 30 100 
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Table 12 
 
IMPROVEMENT OF SIGNS AND SYMPTOMS 
OBSERVED BEFORE AND AFTER 
TREATMENT OF 30 (N) 
PATIENTS OF  NEER PEENISAM  GSMC, CHENNAI – 106. 
 
S.No Signs And Symptoms 
Number Of Patient Percentage 
(%) 
 
Before 
Treatment
After 
Treatment
1 
Itching 
[Nose, eyes, 
throat] 
30 0 100 
2 Sneezing 24 1 95.83 
3 Rhimorrhoea 30 3 90 
4 Nasal block 24 4 83.33 
 
Table 13 
RESULTS OF STATISTICAL ANALYSIS OF 
SUBJECTIVE  PARAMETERS OBSERVED 
BEFORE AND AFTER TREATMENT 
OF 30(N) PATIENTS OF NEERPEENISAM GSMC, CHENNAI 
 
S.no Parameters 
Mean value Difference 
Present 
Statistical 
Test 
criteria 
Probability 
(P) Value 
Statistical 
significanceBefore Treatment 
After 
Treatment
1. Itching [Nose, eyes, throat] 
30.0± 
4.472 
0.01± 
0.01 NIL 16.432 0.001 Significant 
2. Sneezing 24.0± 5.777 
1.0± 
0.242 
23.0± 
0.437 16.432 0.001 Significant 
3. Rhimorrhoea 30.0± 4.472 
3.0± 
0.342 
27.0± 
0.572 16.432 0.001 Significant 
4. Nasal block 24.0± 4.0± 20.0± 16.672 0.001 Significant 
 
Values are compared with test one sample student T.test 
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SUMMARY 
 
In this dissertation Nilavembu chooranam (NVC) was taken to evaluate its 
efficiency on neerpeenisam. 
 
Botanical aspect of the drug Nilavembu (A.paniculata) was studied regarding 
its identification description by pharmacojnostic study. 
 
In Gunapadam aspect Nilavembu chooranam indicated for treating  peenisam 
which is comes under kapha disease so the idea to evaluate the therapeutic 
efficacy  of  this drug in Neer penisam patients carried out at Aringnaranna 
Hospital P.G. Gunapadam Dept. Chennai – 106 
 
Biochemical analysis revealed that the NVC Contains Phosphate, Calcium, 
Sulphate, Chloride,Iron. The pharmacological analysis showed that the drug has 
got anti- inflammatory action in albino rats, anti histaminic action in guie  pig. 
 
Micro biological studies revealed that the drug posses anti microbial activity 
against Straps-mutans.In clinical study 30 patients were selected and treated the 
drug was administered in the form of chooranam at the dose 1 gm twice a day 
with hot water after relevant diet restriction and medical advice were given to 
all the patients. 
 
The clinical study showed that the drug NVC is statistically significant in Neer 
peenisam [allergic rhinitis] and also the symptoms of Sneezing ,Nasal 
discharge, Itching and Nasal obstruction.  
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DISCUSSION AND CONCLUSION 
 
In siddha system of medicine Neer peenisam is caused by increased thosha  like 
kapham and vatham. 
 
In normal body these doshas are statically distributed in normal. But in 
neerpeenism Kapha dosha is increased in the body where the neck to head, is 
ruled by kapha humer. Allergy is the main aggravating factor for this disease. In 
siddha peosepective pancha boothic and arusavai are vital role while treating 
the patients with medicine. According to these theories suvai and  veeriyam of 
the drugs acts against the kapha disease. 
 
The bitter taste drugs we given to patients controls kapham and neutralize 
vatham.  The above tast substance have  vemai veeriam and first against the 
increased  kabam and normalize the kabam  dhosham and neatrolize the 
vatham. 
 
Histamine plays very important role in the early signs and symptoms of allergy 
like vasodilatation, smooth muscle contractions and edema formation. The 
antagonistic action exhibition by NVC for histamine in g.pig ileum shows the 
H1 - receptor antagonistic activity of NVC also exhibition anti peroxides and 
anti oxidant activities in the appropriate experimental models. 
 
Nilavambu is widely used in kabha dosha like  kabha  suram which is mainly 
caused by kabha humer so the activity of  NVC is the drug of choice for neer 
peenisam. 
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Pharmalogical study reveled that NVC have Anti Inflammatory, Anti histaminic 
analgestic activity .  
 
Biochemical analysis the following chemical were found to be present in the 
NVC.Calcium, iron, magnesium, and phosphate.  
 
Iron transport of oxygen to the use of tissue participation in cellular oxidation- 
mechanism. Magnesium  which  help to Keep the mind calm keeps nerves 
relaxed.  
 
Chloride  help in the preservation of the permeability of the cells and normal 
neuromuscular irritability in the ECF and ICF 
 
On clinical study age distribution between 15 to 60 years patients from either 
sex various economical status and habitats were taken for this study. 
 
In this study it is noted that, out of 30 patients sharing this signs and symptoms 
22 patients have good improvement, 5 patients have moderate improvement and 
3 patients shared poor prognosis. 
 
From this study it is revealed that NVC has beneficial effects in Neer Peenisam. 
 
In this preliminary study it was found that Nilavembu Chooranam is an 
effective remedy in the management of Neer Peenisam 
 
This drug is easily available and economical. 
It was well tolerated safe and free from any adverse effect. 
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INTRODUCTION 
 
The disease NINA KURARKAMAL (Enlarged Tonsils) is a world wide health 
problems is a common problem among children and youth due to neglecting oral 
hygiene may allows invasion of micro organisms and cause secondary damage to 
heart values (Rheumatic Fever) and kindly (glumerulonepheritis) it can also leads 
to skin- rashes, sinusitis, pneumonia and ear infection. 
 
The modern surgical management has more complication and also more harmful 
to pharynx so safe remedy is need of the day. 
 
The siddha medical science offer time tested experimental knowledge that can 
provide clues to explore and discover the medicine value of animal origin. 
 
Present study was planned to evaluate the efficacy of SANGU PARPAM on 
Nina kurarkamal  [Enlarged tonsils] .   
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AIM AND OBJECTIVES 
   
The aim of the dissertation work is to assess the efficacy of SANGU 
PARPARAM  IN the management of Nina kurarkhmmal. [Enlarged Tonsils]  
‘Strrep throat’(TONSILLITIS) is a specific type of infection caused by 
streptococcus bacteria can cause Secondary damage to the heart value.                  
(Rheumatic – Fever) and kidney (glamerulonephritis)  so. It is need to treat with . 
herbo-minaral combination of non toxic drug. Sangu Parparam to Prevent cardio 
vascular Events.  
 
Tonsillitis is one of the commonest and major problem among pediatric 
population and young adults. Hence SANGU PARPAM was studied in the 
following aspects. 
 
• ACUTE CHRONIC TOXICITY STUDIES 
• BIO CHEMICAL ANALYSIS 
• ANTI MICROBIAL STUDIES 
• PHARMACOLOGICAL STUDY 
• CLINICAL STUDY. 
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REVIEW  AND LITERATURE 
rq;F 
1) Gunapadam  Aspect: 
NtWngah;fs;:  ee;J Rj;jp ehF tis fk;G NfhL thuzk; nts;is tz;L  
,lk;Ghp rq;fk; Njtjj;jk;. 
kUj;Jtj;jpw;F gad;gLk; rq;F : CJ rq;F 
nghJ Fzk; : rq;fpdhy; ,uj;j gpj;jk; fz;Nzha;fs; thjkpFjp frpT  
%isfl;b Kjypa Neha; ePq;Fk; grpia cz;lhf;Fk;. 
  “frpth kpuj;j gpj;jq; fz;Nzq; NsUk; 
  grpahYk; thjk; gwf;Fk; - kprpTlNd 
 jq;F Kisttpuze; jhsfY} Nknts;isr; 
  rq;fkJ Tz;lhapw;wd;”     Njiuah; 
nra;iffs; 
 cly; cukhf;fp  Jaulf;fp  
 mfl;Lthafw;wp  grpj;jPj;J}z;b 
 Jth;g;gp    ntg;gfw;wp 
 Nfhio mfw;wp. 
kfpikah ke;jhur; rpiyKl; rq;F 
khq;fprr;rpiy kufjkhq; FUttd; lg;gh 
Nghfh; fhurhuj;Jiw 
cgurq;fs; 120 fPo; rq;F tifg;gLj;Jgl;Ls;sJ. 
gQ;rg+j cgurk; : rq;F : mg;G 
mg;Gtpd; Fzk;  : 
  fhrkWk; je;jq; foyhJ NkfKjy; 
  tPR kzy; jzpAk; tPhpakhk; - thrnkd 
  ce;jptsh; Fz;k KepuQ; nrhwpapitNghk; 
           ,e;ehWe; jz;zPUf;Nf. 
jz;zPhpdhy; fz; fhrk; , gpj;j gpuNkfk; gpj;j Fd;kk; ntl;Lfhaq;fspypUe;J  
ngUFk; FUjp nrhwp Mfpait NghFk;. gw;fs; cWjpngUk; 
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“frpthk; ,uj;jgpj;jk; fz;Nzha;fz; MFk;. 
Grpahwk; thjk; gwf;Fk; - ,rpTlNd 
jq;F ehNdh tpuze;jd; mfYNk nts;s  
rq;fkJ cz; Nlah; ehd;” 
       mfj;jpah; ml;ltidthflk;. 
 [e;J Rz;zk;   - cNyhfd; cUf;fTk; Ntijapy;  
ruf;Ffis vhpf;fTk; gad;gLk; 
rq;F NrFk; gpwkUe;;Jfs;    jPUk; Neha;fs; 
fhu kUe;J    - %yk;  
Rq;F ePh;    - Fd;kk; gf;f R+iy 
Jj;jik    - fz;Nzha;;fs; 
jhk;gpuhjp khj;jpiu   - rfytpj fz;Nzha;fs; 
,uj;jpdjp khj;jpiu   - Jh; khkprk; fhr Nuhfk; mkuk; 
gQ;r ghzurk;   - [yNjhrk; 
jpiuNyhf;fpa rpe;jhkzp urk;  - mf;fpdpgyk;  
,yFuh[ kpUfhq;fk;   - fhrk; uh[\ak;   
thj ur $y  khj;jpiu   - fopr;ry; 
thf;fg;gl;l uj;jpdhjp khj;jpiu - fz;Nzha;fz; 
fNde;jpuhjp khj;jpiu  - fz;Nzha;fz; 
rq;F gw;gk;.    - Rthr fhrk; 
 
%is ,uzj;jp;w;U 
 Ky;iyapd; eifaha; rq;fj;jpd; gw;gk;  
 %isapd; ,uz Neha; Nghf;Fk;     
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         itj;a rjfk;  
 
 
 
 
TAXONAMY 
 
KING DOM  : ANIMALIA 
BRANCH  : PROSTOSMIA 
PHXLLUM  : MOLLUSCA 
CLASS  : GACTROPODA 
ORDER  : NEO GASTROPODA 
FAMILY  : TURBINELLIDAE 
GENUS  : XANCUS 
SPECIES  : PYRAM 
 
XANCUS PYRUM   
 
OTHER  NAMES 
 
SANSKRIT   : SHANKHA 
ENGLISH   : CONCH SHELL 
DUK     : SUKK 
GUJ, MAH,KON, GUN :  SHANKHA 
TEL     : SEHKHAM 
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BEN    : SANKH.  
 
DISTRIBUTION 
Abundantly found in   South east coast of India, Areas of gulf of mannar , Palk- 
bay ( T.N. Coast) and Gulf of Kutch. 
CHARACTERS :-  
 
A Porcelaneoas shell of an oblong or conical form the oblong form is bulged in 
the middle and tapering at each and the conical variety and tapering at each and 
the conical verity is  peculiar the upper portion is like cork screw, twisted and 
tapering at the end. The base is broad, the interior is hollow the surface is hard of 
a dull while  color the Upper surface is highly tuborculated. 
 
MEDICINAL USES 
 
Shankha parpam . C. Silicate of Magnesia) does is 2- 6 grains used for ear ache 
ulcers, eye troubles and internally  for dysentery . gonorrhea , colic dyspepsia and 
jaundice , tympani ties. 
 
A compound powder made up of  shanka parpar with  5 bodice seed, 4asofodida 
3 trikaduku and rock salt 4. Each part make it as powder used in colic pain in 
abdomen. 
 
Shank parpam .Ficus religiosa, Borax and aconite is used in catarrh, sore threat, 
cough asthma etc. Does is 2 grams. 
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Kaphakettu rasa containing  conch shell lime is also useful in discharge from ears 
nose etc.  It is used as an expectorant a relives the phlegm. and fever. 
 
 
cj;jhkzp 
PERGULARIA  EXTENSA  (JACG)    
 
NtWngah;fs;  : NtypgUj;jp  cj;jkkhfhzp cj;jk fd;dpif fPhplk; 
 
gad;gLk; cWg;G : ,iy nfhb 
 Rit   : ifg;G 
 jd;ik : ntg;gk; 
 gphpT  : fhh;g;G 
 
nra;iffs;: 
1. Nfhioafw;wp   - Expectorant 
2. Gof;nfhy;yp  - Germicide  
3. the;jpAz;lhf;fp  - Emetic 
 
Fzk; 
 Mypj;njoe;j Neha; mj;jidAe;jPUk; 
Ntypg; gUj;jpajpd; nky; ,iyahy; - Ntnyj;Jf; 
fz;bf;Fk; thjq; fLQ;rd;dp NjhlKk; NghFk; 
cz;bf;Fk; thridahk; XJ. 
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       mfj;jpah; Fzthflk; 
nghopg;Giu: 
 
tspf;Fw;wj;jhYz;lhFk; Neha;fs; Filr;ry; Fj;jy; tPf;fk; eLf;fk; typ Nghd;w 
Neha;fSk; ,iug;G ,Uky; Nfhiof;fl;ly; Mfpa Neha;fSk; jPUk; 
 
 
 
tof;F Kiwfs;  
cj;jhkzp FbePh; - [yNjhrf;jpdhy; cz;lhFk;  thj gpj;j rd;epfspd;  
Njhl tplq;fs; ahTk; ePq;Fk;  
,jd; ,iyr;rhw;iw Rz;zhk;G fye;J fhy;  tPf;fq;fSf;Fk; Nghlyhk; 
,iyapd; tpOijg; gpsitf;Fl;L itj;Jfl;lyhk; 
,jd; ,urk; 5 JspAk; Njd; 5 JspAk;  Nrh;j;J jhkpu nre;J}uk; 12 kpfp cld;  f];Jhp 
12.kpyp Nrh;j;J nfhLf;f Rthrk; jPUk;. 
,J Rz;zhkhf;Fk; nrb  ,jdhy; nra;ag;gLk; gw;gk; kpf fhukha; ,Uf;Fk; 
cj;jhkzpr;rhw;why; rhW  fhJ typ jPUk;. 
 
cj;jhkzp NrUk; gpw kUe;Jfs;  jPUk; Neha;fs; 
 
fz;lf;fj;jphp Nyfpak;   - Rthr fhrk; 
Gdh;thjp Ruzk;    - fhrk; rpNyj;Jkk;  
NtypgUj;jp mil    - ,Uky; 
etr;rhuk; ,e;Jg;G ntq;fhuk;  
NtypgUj;jp; miuj;J Njdpy  - cz;ehf;F tsh;r;rp  
 55
cz;ehf;fpy; jlt  
trk;G khj;jpiu    - Foe;ijfspd; tapw;W typ 
 
fw;Rz;zhj;ij cj;jhkzp rhwwpy; jhspj;J jpdk; ntw;wpiyapy; jltp jhk;Gykhf 
gad;gLj;j fgrd;dPthA jPUk;. 
 
FUgw;gk;      - cj;jhkzpr;rhW – thA jPUk; 
mRtfe;jp vz;nza;    - fhJtyp jPUk; 
 
 
 
BOTANICAL ASPECTS 
TAXONAMY 
 
KINGDOM : PLANT KINGDOM 
DIVISION  : ANGIOSPERMS 
CLASS  : DICOTY LEDONAE 
SUBCLASS : GAMOPETALEA 
SERIES  : BICRAPELLATEA 
ORDER  : GENTIANALES 
FAMILY  : ASCLEPIADACEAE 
GENUS  : PERGULARIA 
SPECIES  : DAEMIA 
(SYN :  PERGULARIA EXTANSA) 
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VERNACULAR NAMES 
SAN   : PHALA KANTAK 
HINDI  : UTRANAJUTUKA 
PUNJ  : TROTTOO 
AUJ   : NAGALADUDHELI 
BEN   : CHHAGAL BATI 
SIND   : KHARYAL  DNDHAVELA 
KAN    : ATTARANI : UTARNI 
TEL   : JITTUPAKU   GURTICHETTU 
MAL   : VELIPERITEE  
CAN   : TALAVARANABALL 
 
 
HABIT  : This common tawnier is found throughout India,   
PART USED : whole plant- leaves roots and root bark. 
 
CONSTITUENTS : Leaves  contain Daemiae Alkaloid Soluble in ether 
alcohol and not Criztalisable The ash from the dried leaves powder has found 
amount  15.33% Pc and bitter glycoside also present. 
 
MEDICINAL USES  
Decoction of the Leaves is given to children as an  anti helmintic. In  does it is a 
good expectorant. Juice  of leaves is useful also in asthma and snakebite. 
 
Powdered leaves in does of 5- 10 grain are also good expectorant. 
 57
 
Externally the juice combined with lime is applied to  Rheumatic swelling.  
Honey is also added to the  decoction  of the leaves to help the expectorant 
effects ( chopra) combined with ginger  the juice  of the  leaves is given  to the 
rheumatism . 
 
Fresh Lanes made in to a pulp are used as a stridulating poultice in carbuncle 
with benefit.  
 
 
 
epzw;Fuw; fk;ky; 
 
njhz;ilf; fl;L Rugq;fk; vd NtW ngah;fshy; Fwpg;gplg;gLk; Fuw; fk;ky; 
Nehapd; xU gphpthFk;. 
cz;zhf;F mow;rp njhz;ilf;fpue;jp tPf;fk;> yrd jhgpjk;. (mz;zhf;F J}W vd;W) 
miof;fg;gLk; Nehapd; Fzq;fs; lhf;lh; R.jpahfuh[d; Fzghlk; jhJ rPt tFg;gpy; 
gf;fk;  487y; Fwpg;gpl;Ls;s Enlarged Tonsils mz;zhf;F J}W Nehapd; 
FwpFzq;fSk; mbg;gilapy; xd;Nw vd;Wk; mz;zhf;F cz;zhf;F xNu Nehia 
Fwpg;gpLtjhf fjpuNth; gps;is jkpo; nkhop mfuhjpapy; njhFjp – 1 y; 
Fwpg;gpl;Ls;shh;. NkYk; cz;zhf;F mow;rpAk; epzFuw;fk;ky; Nehapd; 
FwpFzq;fSk; xNu Nehapid Fwpg;gpLtjhf cs;sJ. 
 
Neha; tUk; top 
1. Fsph; fhw;wpyPLgly; Fsph;e;j nghUs;fis cl;nfhs;sy; 
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2. njhz;ilapy; Gz;gljf;f R++l;by; nte;ePh; gUFjy; 
 
,r;nrayhy; njhz;ilapy; ,Ugf;fq;fSk; jhgpjj;ij cz;lhf;fp, Fuy; tisapd; tPf;fk; , 
njhz;ilapy; , rij tsh;jy;  njhz;il Gz; , ,Uky;  Nghd;w FwpFzq;fs; Vw;gLk; 
 
FwpFzk; 
 
Fuy;tis epzf;Nfhio nfhz;L el td; Nghy; 
tpuT t*g; igf;Uz;ePh; Ntl;if jUNky; 
tzg;Ngh; rwptpz;ik thw; nghWj;J Ngry;  
epze;Fuw; fk;k ndwp 
 
 
1. njhz;il rpte;J Iak; $ba njhz;ilapy; rij tsUk; 
2. ,r;rij tsh;r;rp fl;bfs; Nghy; gFj;J Fuw;fk;ky; Nehia cz;lhf;Fk;. 
3. Ruk;> njhz;il typ tha; ehw;wk; %f;fpy; ePh; tbjy,; fhjpy; rPo; tUjy;> 
,Uky; %r;Rj; jilg;gly; Kjypa Fw;Fzq;fis Vw;gLj;Jk;. 
4. ePh; czT tpOq;f Kbahik 
 
Kf;Fw;wk;. 
 
Ia kpFe;J cjhd thAtpd; jd; td;ikia ,of;fr;nra;Ak; 
 
ehb 
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“jhNdKs;s Nrj;Jke; jhdpsfpy; 
…..…………………. neQ;rilg;G 
,jNkhL ,Wjpehb ,yfplh epWjp epd;why; 
gjnkhL njhz;il fl;Lk; gOj;JneQ;jdpw;fl;Lk;” 
 
        Fz thfl ehb 
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MATERIALS AND METHODS 
 
DRUG PREPARATION 
SOURCE OF COLLECTION :- Sangu ( Conch shell ) Raw drug was 
purchased from the raw drug shop at Chennai. 
 
PURIFICATION OF SANGU : (CONCH SHELL) 
Conch shells were broken into smaller pices and purified by saturated clear 
solution of karchunnam [calcium carbonate]  immerged for 24hrs and boiled, 
then washed with water and dried. 
 
PREPARATION OF PARPAM AND STORAGE 
The purified dried conch shell placed in the uthamani karkam. in a  earthen disc  then it was 
boiled well kept for 3 days in the sun light and covered with same. It was sealed with seven 
layers of clay cloth and dried, then it was subjected to pudam final calicination the parpam . 
further granined well into fine  particles and sieved in white cloth (vastharakeyam) and kept in 
dry clean air light container [Ref. Dr. Thiagarajan. Thathya seeva gunapadam Part II ]  
TEST DRUGS 
The following medicinal plants were used in the study were collected and 
processed by the methods prescribed in standard text books of siddha medicines. 
Sangu Parpam     [ SGP ] 
was prepared by the method described in [Gunapadam Thadhoo Seeva Vaguppu 
Page no  : 487] 
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TOXICITY STUDY 
 
1.1 Preparation of drug for dosing 
All drugs used for the study was suspended each time with 1% (w/v) solution of 
sodium carboxyl methyl cellulose before administration. 
 
1.2 Drugs and chemicals 
Histamine hydrochloride and fine chemicals used in these experiments were 
obtained from Sigma Chemicals company, U.S.A. Other analytical grade 
chemicals were obtained from S.d. Fine Chemicals Ltd., Mumbai. 
 
1.3 Experimental animals  
Colony inbred animals strains of wistar rats of either sex weighing 200 - 250 g 
were used for the pharmacological and toxicological studies. The animals were 
kept under standard conditions 12:12 (day/night cycles) at 220C room 
temperature, in polypropylene cages. The animals were fed on standard palliated 
diet (Hindustan Lever Pvt Ltd., Bangalore) and tap water ad labium. The animals 
were housed for one week in polypropylene cages prior to the experiments to 
acclimatize to laboratory conditions. The experimental protocol was approved by 
the Institutional Animal Ethical Committee (IAEC). 
1.4 ACUTE ORAL TOXICITY STUDY     
Acute oral toxicity was conducted as per the OECD guidelines (Organization of 
Economic Cooperation and Development) 423 (Acute Toxic Class Method). The 
acute toxic class method is a stepwise procedure with 3 animals of a single sex 
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per step. Depending on the mortality and /or moribund status of the animals, on 
the average 2-4 steps may be necessary to allow judgment on the acute toxicity of 
the test substance. This procedure results in the use of a minimal number of 
animals while allowing for acceptable data based scientific conclusion. 
 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) and the 
results allow a substance to be ranked and classified according to the Globally 
Harmonized System (GHS) for the classification of chemicals which cause acute 
toxicity 
 
Wistar albino rats of either sex weighing 200-250 g were fasted overnight, but 
allowed water ad libitum. Since the formulation is relatively non toxic in clinical 
practice the highest dose of 2000 mg/kg/p.o (as per OECD guidelines 
“Unclassified”) was used in the acute toxicity study.   
 
The animals were observed closely for behavioral toxicity, if any by using FOB 
(Functional observation battery). 
 
1.5 REPEATED ORAL TOXICITY STUDY  
Repeated oral toxicity studies can be used to get additional information regarding 
the toxicity profile of a chemical. Repeated oral toxicity studies are defined as 
those studies where the chemical is administered to the animal for a period 
covering approximately 10% of the expected life of the animal. Usually, the dose 
levels are lower than for acute studies and allow chemicals to accumulate in the 
body before lethality occurs, if the chemical possess this ability. 
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1.6 Experimental procedure 
The following experimental procedure was followed to evaluate the repeated oral 
toxicity study of - 
SANGU PARPAM  (SGP)   
Group I : Control animals received 1% Sodium carboxyl methyl 
cellulose (CMC), ml/kg/p.o. for 21 days   
Group II      :  Drugs suspended in CMC was given at the dose Level of 500 
mg/kg/p.o. for 21 days 
Body weight, food intake and water intake was recorded at two intervals with 
simultaneous observation for toxic manifestation and mortality, if any. At the end 
of 21 days treatment all the animals were sacrificed by over dosage of ether 
anesthesia. Blood was collected and used for hematological studies. Section of 
liver, kidney, and heart were dissected out and kept in 10% formalin for 
histopathological studies. 
1.7 Acute oral toxicity study 
SGP at the dose of 2000mg/kg/po did not exhibit any mortality in rats. As per 
OECD 423 guidelines the dose is said to be “Unclassified” under the toxicity 
scale. Hence further study with higher doses was not executed.  
 
1.8 Repeated oral toxicity for 21 days 
Test drug SGP at the dose of 500 mg/kg/po when administered orally for 21 days 
in rats did not show toxicity in renal functions. There was an significant increase 
in % of Hb and RBC (Table 2 ). However the drug did not show any significant 
elevation of marker enzyme levels of liver (Table 3). 
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TABLE 1 
EFFECT OF SIDDHA FORMULATIONS (NVE) ON 
HAEMATOLOGICAL PARAMETERS AFTER 15 DAYS REPEATED 
ORAL DOSING (500 MG/KG) 
Groups Hb 
(gm/100m
l) 
RBC 
(millions/
cu.mm) 
WBC 
(cells/cu.m
m) 
Differential leucocyte count (%) 
Lympho 
cytes 
Mono 
cytes 
Granulo 
cytes 
Normal 13.08 ± 
0.34 
4.31 ± 
0.35  
54850 ± 
9.44 
76.06 ± 
3.89  
5.30 ± 
1.04 
16.50 ±  
4.27 
NVE 
(500mg/
kg/p.o) 
13.68 ± 
0.70 ns 
4.68 ± 
0.72 ns 
5786.66 ± 
3.323 
77.67 ± 
3.32 ns 
8.16 ± 
1.7 ns  
16.66 ± 
3.44 ns 
n=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
ns – non significant when compared to control groups  
TABLE 2 
EFFECT OF SIDDHA FORMULATION (NVE) ON BIOCHEMICAL 
MARKERS OF LIVER AND KIDNEY AFTER 15 DAYS REPEATED 
ORAL DOSING (500 MG/KG/PO) IN RATS 
Groups ALP 
(K.A.Units) 
AST  
(IU/L) 
ALT  
(IU/L) 
Urea 
(mg/100ml) 
BUN 
(mg/ 100ml) 
Normal 3.78±0.38 78.48±0.23  28.70 ± 
0.81 
13.56 ± 0.37 6.48 ± 0.50 
NVE 
(500mg/kg/p.o) 
4.32±0.75ns 79.55±5.92
ns 
30.13 ± 
2.67 ns 
14.60 ± 0.69 
ns 
7.51 ± 0.35 ns
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
Ns – non significant when compared to control groups  
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BIOCHEMICAL STUDIES 
 
ASPARTATE AMINOTRANSFERASE (AST) 
Aspirate aminotransferase was estimated using commercial AST kit (Span 
Diagnostics) by the method of Reitman and Frankel (1957). 
Alanine aminotransferase (ALT) 
Alanine aminotransferase was estimated using commercial AST kit (Span 
Diagnostics) by the method of Reitman and Frankel (1957). 
Alkaline phosphatase (ALP) 
Alkaline phosphatase was assayed using commercial ALP kit (Span Diagnostics)  
by the method of King (1934). 
Urea   
Urea was assayed using the commercial kit (Span Diagnostics) by the method of 
Coulambe  et al., (1965). 
1.8 Haematological studies 
Erythrocyte count 
Erythrocyte count was estimated by Hemocytometer method of Ghai (1995). 
Total Leukocyte Count (WBC) 
Total Leukocyte Count was estimated by Hemocytometer method of John (1972). 
Haemoglobin  
Haemoglobin was estimated by method of Ghai (1995). 
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TABLE 3 
EFFECT OF SIDDHA FORMULATIONS (SGP) ON 
HAEMATOLOGICAL PARAMETERS AFTER 15 DAYS REPEATED 
ORAL DOSING (500 MG/KG) 
 
Groups Hb 
(gm/100m
l) 
RBC 
(millions/
cu.mm) 
WBC 
(cells/cu.m
m) 
Differential leucocyte count (%) 
Lympho 
cytes 
Mono 
cytes 
Granulo 
cytes 
Normal 13.08 ± 
0.34 
4.31 ± 
0.35  
54850 ± 
9.44 
76.06 ± 
3.89  
5.30 ± 
1.04 
16.50 ±  
4.27 
SGP 
(500mg/
kg/p.o) 
13.98 ± 
0.70 ns 
4.58 ± 
0.72 ns 
5686.66 ± 
3.323 
78.67 ± 
3.32 ns 
8.16 ± 
1.7 ns  
15.66 ± 
3.44 ns 
n=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
ns – non significant when compared to control groups  
TABLE 4 
EFFECT OF SIDDHA FORMULATION (SGP) ON BIOCHEMICAL 
MARKERS OF LIVER AND KIDNEY AFTER 15 DAYS REPEATED 
ORAL DOSING (500 MG/KG/PO) IN RATS 
 
Groups ALP 
(K.A.Units) 
AST  
(IU/L) 
ALT  
(IU/L) 
Urea 
(mg/100ml) 
BUN 
(mg/ 100ml) 
Normal 3.78±0.38 76.48±0.23  28.70 ± 
0.81 
13.56 ± 0.37 6.48 ± 0.50 
SGP 
(500mg/kg/p.o) 
4.32±0.75ns 89.55±5.92
ns 
32.13 ± 
2.67 ns 
15.60 ± 0.69 
ns 
7.61 ± 0.35 ns
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
Ns – non significant when compared to control groups  
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PHARMACOLOGY STUDIES 
 
ANALGESIC ACTIVITY 
 
TAIL FLICK METHOD 
Withdrawal of tail (Tail Flick) for noxious thermal (radiant heat) can be used for 
screening drugs with analgesic activity. Radiant heat can be generated by passing 
electrical current through nichrome wire mounted in an analgesiometer. 
 
The base of the tail of the test rats is placed on a nicrome wire. The tail 
withdrawal for the radiant heat (flicking response) is taken as the end point. 
Normally the rats and mice withdraw their tails within 3 – 5 secs. A cutoff time 
of 10 – 12 secs is used to prevent damage to the tail. Any animal failing to 
withdraw its tail in 3-5 secs is rejected from the study.  
 
The reaction time of test drug, standard and control are taken at intervals of 30, 
60 and 120 mts. A reaction time (withdrawal time) increment of 2-5 secs more 
than the control animals can be considered for analgesic activity of the drug.  
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TABLE 5 
 
ANALGESIC ACTIVITY OF SGP  USING TAIL FLICK  METHOD 
 
Groups Paw licking response  (Sec) 
0 min 
( Sec) 
30 min 
( Sec ) 
60 min 
(Sec ) 
120 min 
(Sec) 
Control 1.56 ±  
0.96
1.86 ± 
0.96
1.76 ± 
0.67
1.86 ±  
0.53 
Test 
(500mg/kg. 
p.o.,) 
1.86 ±  
 0.206 
ns 
2.367 ± 
0.265 
*** 
4.866 ± 
1.267 
*** 
5.8  ± 
0.4336 
*** 
 
       n=6,  Values are expressed as mean ± S.D using followed  
       by student paired T – test , ns- non significance 
             ***P<0.001 as compared with control.  
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ANTI INFLAMMATORY ACTIVITY 
 
Anti inflammatory activity was evaluated in acute model of inflammation.  
 
Acute model 
 
Carrageenan  induced hind paw edema  
 
 The carrageenan assay procedure was carried out according to the 
method of Wintar et al. (1962). Edema was induced by injecting 0.1 ml of 1% 
solution of carrageenan in saline into the plantar aponeurosis of the left hind paw 
of the rats.  The extracts, reference drug and the control vehicle (distilled water) 
were administered 60 min prior to the injection of the carrageenan. The volumes 
of edema of the injected and contra lateral paws were measured at +1, 3 and 5 hrs 
after induction of inflammation using a plethysmometer (Bhatt et al., 1977) and 
percentage of anti-inflammatory activity was calculated.   
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TABLE 6 
ANTI INFLAMMATORY ACTIVITY OF  SGP  
INDUCED END PAW EDEMA IN RATS 
Groups Paw volume ( ml) by mercury Displacement 
at regular interval of time 
0min 30min 60min 120min 240min 15 hrs 
Control 
 
 
1.323 ± 
0.1549 
1.60± 
0..225 
1.933± 
0.242 
2.066 ± 
0.258 
2.200± 
0.236 
2.200± 
0.236 
SGP 
(500mg/kg. 
p.o.,) 
1.323 ± 
0.338 
ns 
1.67 ± 
0.426 
ns 
2.03 ± 
0.2366 
ns 
1.650± 
0.316 
*** 
1.500 ± 
0.312 
*** 
1.533 ± 
0.372 
*** 
Standard 
(Dic.Sodium 
5 mg/kg/po) 
0.835 ± 
0.065 ns 
1.315 ± 
0.069ns 
1.128 ± 
0.049***
1.011 ± 
0.056*** 
0.896 ± 
0.048***
0. 85 ± 
0.054 
*** 
 
n=6; Values are expressed as mean ± S.D followed by student                   
paired T- test. ns - Non significant as compared with control; 
                                P< 0.001 (***) as compared with control. 
 
Results 
 
SGP showed anti-inflammatory activity in carrageen an induced hind paw edema 
in rats. The anti-inflammatory activity was observed at the end of 2 hrs after the 
pre treatment drug whereas the standard drug diclofenac sodium exhibited 
reduction in edema volume at the end of 1 hr after administration.     
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ANTI MICROBIAL STUDY 
 
Paper disc diffusion method 
 
The sterilized (autoclaved at 120 o C for 30 min ) medium ( 40-50 o C ) was 
inoculated ( 1 ml / 100 ml of medium ) with the suspension ( 10 5 cfu mL -1 ) of 
the microorganism ( matched to Mc Farland  barium sulphate standard ) and 
poured in to a Petri- dish to give depth of 3-4 mm. The paper impregnated with 
the test compounds ( 25, 50, and 100 µg mL-1in dimethyl farmamide ) was placed 
on the solidified medium. The plates were pre incubated for 1 h at RT and 
incubated at 37o C for 24 and 48 h for anti bacterial and anti fungal activities, 
respectively. Ciprofloxin ( 100 μg /10 disc ) and ketoconozole ( 100 µg/ disc ) 
were used as standard for anti bacterial and anti fungal activities, respectively. 
The observed zone of inhibition is presented in table  
 
In-vitro antimicrobial activity of SGP was screened against bacteria  and yeast 
strains. The results are depicted in Table 14. SGP were  exhibited low 
antimicrobial activity in streptococcus mutans in 10 μl / disc. Others were 
exhibited  moderate to high antibacterial activity when compared to standard 
drugs ciprofloxacin and ketoconozole respectively. 
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TABLE  7 
 
Zone of inhibition in mm 
Organism Standard 
drug 
Ciprofloxacin 
50 mcg/disc 
Test drug (SGP µl/disc ) 
Zone of inhibition in mm 
10μl 25μl 50μl 
Strep. mutans 31 14 16 19 
Staph. aurens 31 15 20 23 
E.coli 30 16 23 26 
K.pneumoniae 31 16 20 24 
Ps.areginosa 30 16 19 23 
Group A 
Streptococcus. 
31 15 17 22 
 
14 mm – Low sensitive,  15 mm – Moderate, above 16 mm – Highly sensitive 
Note Sample concentration  :-  
4 gm – 400 ml of solvent  in 25 µl, 50 µl, and 100 µl / disc standard for Bacteria  
;- Ciprofloxacin HCl, 50 mcg / disc. 
 
In-vitro antimicrobial activity of SGP as screened against bacteria and yeast 
strains. The results are depicted in Table 13. In 10 μl/disc concentration of SGP 
were exhibited  low antibacterial activity in Group A streptococcus and Staph. 
aereus. others were exhibited moderate to high antibacterial activity when 
compared to standard drugs ciprofloxacin and ketoconozole respectively. 
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ANTIOXIDANT STUDY 
 
1.10 In Vivo Antioxidant study 
 
Samples of serum collected from  rats treated with test drugs were assayed 
for GSH (Moron et al , 1979)  and LPO (Yagi, 1976)  and the results were 
compared with  control group. 
 
 
                      Table  8 
 
Anti oxidant activity of Siddha Formulation (NVE )  
after 15 days repeated oral dosing (500 mg/kg) 
 
Groups LPO GSH 
 
Control 0.63 ± 1.37 46.28 ± 2.31 
 
NVE 
(500mg/kg/p.o) 
0.42 ± 3.90*** 83.31 ± 0.35*** 
 
 
 
N=6; Values are expressed as mean ± S.D followed by Student T- Test. 
***P<0.001 as compared with control.  
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2.6 ANTIOXIDANT ACTIVITY  
 
At the end of 21 days repeated oral toxicity study when the plasma of drug 
treated animals was examined for GSH activity, the level of GSH activity was 
increased significantly (p>0.001) in test groups. On the other hand the LPO 
activity was considerably reduced in drug treated group when compared to 
control. 
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CLINICAL ASSESSMENT 
1. STUDY DESIGN 
 
1. Open clinical trial  
 
2. Parameters  for evaluation 
  
 
2. SYMPTOMS AND SIGN 
Thondai  vali [pain]  
Vizingupothu vali [pain on swallowing ] 
Thondai sathai veekam [Enlarged tonsils] 
Kurarkammal [ Change of voice] 
Thondai Sivathal [ Redness of Pharynges ] 
 
3.  LINE OF TREATMENT     
 
     Dose : 260 mg bid twice daily Anupanam: honey  
     Route of administration  enternal  
     Duration : 45 days 
 
 4.       SELECTION PATIENTS: 
 
 Sample size 24 patients total number of number of 24 patients total number 
of 24 patients are selected on the basis of inclusion and exclusion criteria . 
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INCLUSION CRITERIA      EXCLUSION CRITERIA  
 
1. History sign and  symptoms of   1. Quinsy 
Ninakurarkammal    
2. Parapharyngea  abscess 
2. Age between 10-50 years   
from either sex       3. Rheumatic fever endocardities 
       
       4. Acute glomerulo nephritis 
   
   5. Septicemia 
   
   6. 10 t who have any offer  
concomitant illness 
 
7.       10t with know liver  or    
            kidney disorders 
 
DIAGNOSIS 
 
Diagnosis is made by physical  examination signs and symptoms of 
the Disease. 
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LABORATORY DIAGNOSIS  
 
Blood 1) Leukocytosis [12,000 cells/cumm – 20000cells/cumm] 
With predominant polymorphonclear cells 
          2) ESR is Raised 
 
Repaid detection method for streptococcal antigen or by culturing after 
pharyngeal  
swabbing, may be positive for streptococci in streptococcal tonsillitis. 
 
 
 
 
BLOOD TEST FOR    URINE 
 
¾ TCL     ALB 
 
¾ DC     SUG 
 
¾ ESR     DEP 
 
¾ HB 
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MEDICAL ADVICE 
Advice regarding personal hygiene  
Improving general health 
 
All the 24 patients were subjected for the clinical study age socio economic status  
personals habits and diets occupational status signs and symptoms during 
admission where recorded improvement showing signs and symptoms and 
statistical analysis after treatment is recorded and tabulated as follows. 
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Table  9 
SEX DISTRIBUTION 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.N SEX No of Patients Percentage 
1 Male 11 45.8 
2 Female 12 50 
3 Children’s 1 4.2 
 Total 24 100 
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AGE WISE DISTRIBUTION
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Table  10 
 
AGE WISE DISTRIBUTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.N Age in years No of Patients Percentage 
1 10 – 20 16 66.6 
2 21 – 30 6 25 
3 31 – 40 1 4.2 
4 41 – 50 1 4.2 
 Total 24 100 
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Table  11 
SOCIO-ECONOMIC STATUS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.N Eco. Status No of Patients Percentage 
1 Poor 3 12.5 
2 Middle 20 83.3 
3 Rich 1 4.2 
 Total 24 100 
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DIET
Vegetarian
Mixed Diet
Table  12 
DIET 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.N Diet No of Patients Percentage 
1 Vegetarian 1 4.2 
2 Mixed Diet 23 95.8 
 Total 24 100 
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Table  13 
 
OCCUPATIONAL STATUS 
 
 
 
 
 
 
 
 
 
 
                                            
 
 
 
 
S.N Occupation  No of Patients Percentage 
1 Daily Labor’s 5 20.8 
2 Students 6 25 
3. House wife 5 20.8 
4. Office worker 5 20.8 
5 Business 3 12.6 
 Total 24 100 
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Table  14 
 
IMPROVEMENT OF SIGNS AND SYMPTOMS 
 OBSERVED BEFORE AND AFTER  
TREATMENT OF 24 (N) 
 PATIENTS OF  NINAKURAR KAMAL GSMC, CHENNAI – 106. 
 
 
S.NO 
SIGNS AND 
SYMPTOMS
NUMBER OF 
PATIENT PERCENTAGE
 Before  
Treatment
After  
Treatment
1 Throat pain  24 3 87.5 
2 Cough 20 4 80 
3 
Change of 
voice 
15 3 80 
4 
Enlarged 
tonsils 
12 3 83.33 
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Table  15 
 
RESULTS OF STATISTICAL ANALYSIS OF  
SUBJECTIVE  PARAMETERS OBSERVED  
BEFORE AND AFTER TREATMENT  
OF 24(N) PATIENTS OF NINAKURARKAMAL GSMC, CHENNAI 
 
 
S/n Parameters 
Mean value 
Difference 
Present 
Statistical 
Test 
criteria 
Probability 
(P) Value 
Statistical 
significance
Before 
Treatment 
After 
Treatment
1. 
Throat 
pain  
34.0± 
3.577 
3.0± 
0.894 
21.0± 
3.128 
16.432 0.001 
Significant 
2. Cough 
20.0± 
4.472 
4.0± 
1.7889 
16.0± 
3.621 
10.954 0.001 
Significant 
3. 
Change of 
voice 
15.0± 
4.472 
3.0± 
0.894 
12.0± 
2.752 
8.2161 0.001 
Significant 
4. 
Enlarged 
tonsils 
18.0± 
1.788 
3.0± 
0.894 
150± 
2.872 
24.648 0.001 
Significant 
 
Values are compared with test one sample student T.test  
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SUMMARY 
 
The Sangu Parpam [SGP] was taken to evaluate its efficacy on Ninakurarkammal. 
 
Zoological and Botanical of the raw drugs were studied regarding its identification and 
description. 
 
The Sangu Parpam prepared indicated for treating Ninakurarkamal enlarged tonsils which 
comes under kabha disease. So the plen to evaluate the therapeutic efficacy of this drug in 
Ninakurarkamal patients, carried out at  Aringnar Anna Hospital post graduate Gunapadam 
out patient department Chennai – 106.  
 
Bio Chemical analysis the SGP Contains Calcium, Carbonate, Chloride. 
 
The pharmacology analysis showed that the drug has got mild anti inflammatory analgesic, 
antihistaminic, pyuretic  animal study the clinical study was done in 24 patients after 45 
days course of treatment good response was observed in 18 cases 3 cases showed fair 
response 3 cases showed poor response. 
The drug Sanguparpam is stasistically significant in improving Ninakurarkammal digest 
signs and symptoms  
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DISCUSSION AND CONCLUSION 
   The incinerated Sangu parpam SGP Considered to be 
KARPPU [ Acrid ] Taste. Which is Normalizing  the Kaba thodam in 
Ninakurarkammal.  
 
Even honey the adjuvant for the drug has expectorant and antiseptic action 
SGP Exhibition anti– inflammatory and analgesic activities in appropriate 
experimental models. The delayed anti– inflammatory activity of  SGP in 
carrageenan induced edema may be due to the delayed absorption of activity 
constituent of the drug from GI tract or a mechanism by which SGP inhibits the 
synthesis or release of inflammatory prostaglandins from the site of chemical 
injury (carrageenan) SGP exhibited analgesic activity in the radiant heat method 
in rats. There is a good correlation of results obtained from the experimental 
study vi-a-vis the clinical study reported in the thesis. 
 
The total leukocyte count and ESR are indicates level of infection associated with 
infection dropped  to  normal. Proving that Sangu parpam had influenced the 
disease state So it is concluded that for the disease Ninnakurakammal the 
treatment with Sangu Parpam is good in the view of efficacy and safe.  
 
It was found that Snagu Parpam is an effective remedy in the management of 
Ninakurarkamal discus is easily available and economical. It was well tolerated, 
safe and free from any adverse effect. 
Result
P L E 1/2 HR 1 HR
BT 10100 53 39 8 22 45 10.2 N N OPC
AT 11600 51 35 8 10 30 12.5 N N OPC
BT 8900 54 40 6 7 14 10.5 N N N
AT 8800 58 38 6 3 7 11 N N N
BT 11200 56 32 12 38 65 12.5 N N N
AT 10600 56 38 6 22 40 13 N N N
BT 10300 58 30 12 12 25 14 N N N
AT 10000 51 47 2 7 15 14 N N N
BT 9100 58 40 2 5 12 12 N N N
URINE
Mani 20/M
HB % HB SUG DEP
18 6 Bh hi 10/M L f i h h
4 1502 Srinivasan 19/F Throar Pain Cough Feverish
3 1500 Balu 21/m Cough. Change of voice sore throat
2 1493 sore Throat difficulty in swallowing 
1 1414 Jothika 30/F Throat Pain Fullness in the Throat . Malise
CLINICAL STUDY ON SANGU PARPAM IN O.P DEPARTMENT IN THE MANAGEMENT OF                             
NINA  KURAR  KAMAL
Blood
S/N OP.NO NAMES AGE/SEX                COMPLAINTS
B/T      
A/T TLC
DC (%) ESR (MM)
G d
Good 
Good 
Moderate
Good 
AT 9000 60 38 2 5 10 12 N N N
BT 12600 52 42 6 15 30 12.2 N N FEC
AT 11200 54 40 6 10 20 12.3 N N FEC
BT 11600 52 38 10 29 52 13 N N N
AT 10600 54 37 7 5 11 13 N N N
BT 10200 70 22 8 40 120 11.5 N N FEC
AT 11058 58 40 2 34 70 11.5 N N FEC'
BT 8800 52 41 7 22 60 13.5 N N N
AT 8600 54 40 6 18 40 13.5 N N N
BT 10800 64 31 5 18 40 13.5 N N N
AT 10400 65 32 3 10 18 13.5 N N N
BT 10700 62 33 5 6 12 14 N N N
AT 10100 65 33 2 6 11 14 N N N
BT 12200 56 40 4 15 32 14.2 N N N
AT 11600 58 38 4 6 12 14.2 N N N
BT 10200 53 39 8 44 70 13.5 N N N
AT 10000 62 33 5 15 25 13.5 N N N
13 2147 Rajasekar / 17/M Sore throat fever , cough
12 2152 Rajesh 20/M Throat pain difficulty  in swalling
11 2096 Vadivelu 17/F Sore throat nasal Discharge cough
10 2123 Sankar 19/M Throat pain difficulty in swallowng malise
9 2089 Ravichandran 16/M Throat pain cough lose of appetite 
8 2091 Aswini 19/F Sore throat cough headach
7 1831 Gokul 15/M Throat pain Cough, Malise running Nose
6 1826 Tamilselvi 23/F Difficulty in swallowing malise sore throat
5 5 arat  oss o  appet te coug  sore t roat oo  
Moderate
Good 
Mild
Good 
Good 
Good 
Good 
Good 
BT 10000 60 35 5 60 124 12.8 N N FEC
AT 9600 62 33 5 35 68 12 N N FEC
BT 10600 48 38 14 12 26 4 N N N
AT 9800 52 38 10 5 11 14 N N N
BT 11200 48 40 12 40 80 11.5 N N OPC
AT 11400 50 40 10 45 90 11.5 N N OPC
BT 12100 56 38 6 16 34 13 N N N
AT 10400 58 38 4 20 42 13 N N N
BT 9700 59 35 6 22 40 10.5 N N FEC
AT 9000 70 36 4 5 11 11 N N FEC
BT 9200 54 41 7 10 20 9.5 N N OPC
AT 8600 56 35 5 55 11 9.5 N N OPC
BT 9000 58 38 6 12 25 9 N N FEC
AT 9600 56 36 6 12 26 9 N N FEC20 5921 Nazhima
Throat Pain Fullness of throat 
Feverish
19 5837 Sowmya 22/F Cough Sore Throat,
18 4389 Vimala 20/F Sore throat headache ear discharge
17 4401 Masilamani  19/M Throat pain dysphagia loss of appotite
16 3067 Sudalakrishmi  16/F Throat Pain cough 
15 3070 Vasu 17/M
Fullness in the Throat , Malise sore 
throat
14 2917 Suselar 19/F Cough Thrat pain malise
Moderate
Mild
Moderate
Good 
Good 
Good 
Mild
BT 9000 56 38 6 11 25 9.5 N N FEC
AT 8100 55 37 8 6 12 9.5 N N FEC
BT 8600 56 38 6 11 25 10.5 N N OPC
AT 8100 61 35 4 6 14 11 N N N
BT 11800 60 39 1 21 40 14.5 N N FEC
AT 9600 55 36 9 12 24 14.5 N N N
BT 13200 48 42 10 30 64 13.5 N N OPC
AT 13400 52 42 6 40 85 13.5 N N OPC24 7221 Johnson 44/M Fever sore throat malise
23 6828 Jeyaganesan  27/M
Throat pain difficulty in swallowng 
cough
22 6366 Tharuniza 37/F sore throat cough nasal discharge
21 6454 Kamatchi 37/F Throat pain oral ulcer cough
Good 
Good 
Good 
Poor
Abbrevation :
BT - Befor Treatment, AT - After Treatment, TC - Total WBC Count, DC - Differential Count, Hb - Haemoglobin,       Alb -
Aibumin, Dep - Deposit, OPC - Occasional Puss Cells, FPC - Few Cells, FPC - Few pus cells, N- Nil,    
P - Neutrophills, L - Lymphocyte, E - Easinophills.
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